scispace - formally typeset
Open AccessJournal ArticleDOI

Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials

Reads0
Chats0
TLDR
Based on the current clinical trials, MSC therapy appears safe, however, further larger scale controlled clinical trials with rigorous reporting of adverse events are required to further define the safety profile of MSCs.
Abstract
Background Mesenchymal stromal cells (MSCs, “adult stem cells”) have been widely used experimentally in a variety of clinical contexts. There is interest in using these cells in critical illness, however, the safety profile of these cells is not well known. We thus conducted a systematic review of clinical trials that examined the use MSCs to evaluate their safety. Methods and Findings MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (to June 2011), were searched. Prospective clinical trials that used intravascular delivery of MSCs (intravenously or intra-arterially) in adult populations or mixed adult and pediatric populations were identified. Studies using differentiated MSCs or additional cell types were excluded. The primary outcome adverse events were grouped according to immediate events (acute infusional toxicity, fever), organ system complications, infection, and longer term adverse events (death, malignancy). 2347 citations were reviewed and 36 studies met inclusion criteria. A total of 1012 participants with clinical conditions of ischemic stroke, Crohn's disease, cardiomyopathy, myocardial infarction, graft versus host disease, and healthy volunteers were included. Eight studies were randomized control trials (RCTs) and enrolled 321 participants. Meta-analysis of the RCTs did not detect an association between acute infusional toxicity, organ system complications, infection, death or malignancy. There was a significant association between MSCs and transient fever. Conclusions Based on the current clinical trials, MSC therapy appears safe. However, further larger scale controlled clinical trials with rigorous reporting of adverse events are required to further define the safety profile of MSCs.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Mesenchymal stem cells: immune evasive, not immune privileged

TL;DR: Protecting MSCs from immune detection and prolonging their persistence in vivo may improve clinical outcomes and prevent patient sensitization toward donor antigens.
Journal ArticleDOI

Clinical Trials with Mesenchymal Stem Cells: An Update:

TL;DR: Clinical trials using MSCs for representative diseases, including hematological disease, graft-versus-host disease, organ transplantation, diabetes, inflammatory diseases, and diseases in the liver, kidney, and lung are analyzed, as well as cardiovascular, bone and cartilage, neurological, and autoimmune diseases.
Journal ArticleDOI

Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities

TL;DR: Important biological and pharmacological disparities in pre-clinical research and human translational studies are highlighted, and analyses of clinical trial failures and recent successes provide a rational pathway to MSC regulatory approval and deployment for disorders with unmet medical needs.
Journal ArticleDOI

Mesenchymal Stem Cells for Regenerative Medicine.

TL;DR: A brief overview of MSC extraction methods and subsequent potential for differentiation is presented, and a comprehensive overview of their preclinical and clinical applications in regenerative medicine is presented.
Journal ArticleDOI

Extracellular vesicles as drug delivery systems: Why and how?

TL;DR: Unique EV features that are relevant for drug delivery are reviewed and emerging strategies to make use of those features for drug loading and targeted delivery are highlighted.
References
More filters
Book

Cochrane Handbook for Systematic Reviews of Interventions

TL;DR: The Cochrane Handbook for Systematic Reviews of Interventions is the official document that describes in detail the process of preparing and maintaining Cochrane systematic reviews on the effects of healthcare interventions.
Journal ArticleDOI

Mesenchymal stem cells in health and disease

TL;DR: The targets and mechanisms of M SC-mediated immunomodulation and the possible translation of MSCs to new therapeutic approaches are discussed.
Journal ArticleDOI

HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.

TL;DR: Undifferentiated and differentiated MSC do not elicit alloreactive lymphocyte proliferative responses and modulate immune responses, and the findings support that MSC can be transplantable between HLA-incompatible individuals.
Related Papers (5)